Status:
COMPLETED
N-acetylcysteine to Reduce Ischemia/Reperfusion Injury in Liver Resection
Lead Sponsor:
Clinica Universidad de Navarra, Universidad de Navarra
Conditions:
Hepatectomy
Reperfusion Injury
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
Study hypothesis: N-acetylcysteine (NAC) can reduce ischemia/reperfusion injury in liver resection performed under ischemic preconditioning and intermittent portal triad clamping.
Detailed Description
One of the most important factors in the pathophysiology of liver dysfunction after hepatic surgery is the cellular damage derived from the interruption of blood flood with reperfusion of the organ. N...
Eligibility Criteria
Inclusion
- Hepatectomy
Exclusion
- ASA 4
- Cirrhosis
- Creatinine \> 1.2 mg/dL
- Associate surgery (pancreatic or splenectomy)
- Intraoperative bleeding \> 2 L.
- Active infection of inflammatory disease
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT01223326
Start Date
January 1 2003
End Date
December 1 2007
Last Update
June 8 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinica Universidad de Navarra
Pamplona, Navarre, Spain, 31008